Teladoc Health, Inc. TDOC · NYSE
$5.67 -5.03% (-$0.30)
Summary
44 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
What to watch
- The company made a loss over the last 12 months.
- Revenue growth is slowing: 1.7% a year over the last 3 years against 18% over 5 years.
- Analysts expect revenue to fall by 4.9% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 1.7% a year. For the next fiscal year analysts expect revenue to fall by 4.9%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $177.4M.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 15
- Hold 27
- Sell 0
Today's price within the analysts' price targets
The average target of $8.83 is 56% above today's price. 36% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other 100%
By region
- UNITED STATES 82%
- Non-US 18%
Other brings in 100% of revenue.
Segments in detail